Compare USNA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | AUTL |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.2M | 388.6M |
| IPO Year | 1996 | 2025 |
| Metric | USNA | AUTL |
|---|---|---|
| Price | $21.51 | $1.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 108.9K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,060,902,000.00 | $10,120,000.00 |
| Revenue This Year | $3.90 | $80.32 |
| Revenue Next Year | $6.21 | $53.96 |
| P/E Ratio | $52.46 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $16.60 | $1.18 |
| 52 Week High | $38.32 | $2.70 |
| Indicator | USNA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 67.62 | 49.39 |
| Support Level | $18.71 | $1.38 |
| Resistance Level | $22.71 | $1.73 |
| Average True Range (ATR) | 0.82 | 0.10 |
| MACD | 0.26 | 0.01 |
| Stochastic Oscillator | 88.48 | 46.15 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.